---
title: "China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280081717.md"
description: "China Resources Pharma announced that its subsidiary CR Sanjiu achieved an annual revenue of RMB 31.603 billion (the same below) for the year ending last December, an increase of 14.4% year-on-year. The net profit was RMB 3.421 billion, an increase of 1.58% year-on-year; the net profit excluding non-recurring items was RMB 3.134 billion, an increase of 0.5% year-on-year; earnings per share were RMB 2.06. A cash dividend of 59 cents (tax included) per share will be distributed to all shareholders of CR Sanjiu"
datetime: "2026-03-23T01:35:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280081717.md)
  - [en](https://longbridge.com/en/news/280081717.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280081717.md)
---

# China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMB

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu (000999.SZ) reported an annual revenue of RMB 31.603 billion for the year ending December last year, an increase of 14.4% year-on-year. The net profit was RMB 3.421 billion, up 1.58% year-on-year; the net profit excluding non-recurring items was RMB 3.134 billion, an increase of 0.5% year-on-year; earnings per share were RMB 2.06. A cash dividend of 59 cents per share (before tax) will be distributed to all shareholders of China Resources Sanjiu

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [000999.CN](https://longbridge.com/en/quote/000999.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)

## Related News & Research

- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)